Company Overview of Zafgen, Inc.
Zafgen, Inc., a biopharmaceutical company, focuses on the provision of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical trials reduces the severity of nonalcoholic steatohepatitis and plasma glucose. Zafgen, Inc. was founded in 2005 and is headquartered in Cambridge, Massa...
Cambridge, MA 02142
Founded in 2005
Key Executives for Zafgen, Inc.
Chief Executive Officer and Director
Total Annual Compensation: $425.0K
Total Annual Compensation: $195.4K
Chief Financial Officer
Total Annual Compensation: $297.9K
Chief Medical Officer
Total Annual Compensation: $407.0K
Chief Commercial Officer
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.
Zafgen, Inc. Key Developments
Zafgen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 02:35 PM
Feb 18 15
Zafgen, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-25-2015 02:35 PM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.
Zafgen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM
Jan 30 15
Zafgen, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 03:30 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.
Zafgen Announces Positive Results from Phase 2 Clinical Trial of Beloranib in Hypothalamic Injury Associated Obesity
Jan 7 15
Zafgen announced that ZAF-221, a randomized, double-blind, placebo-controlled Phase 2 clinical trial of beloranib, a MetAP2 inhibitor, in 14 adults with hypothalamic injury associated obesity, or HIAO, met the primary efficacy endpoint of weight reduction (p = 0.01). In addition, beloranib treatment was well-tolerated and improved cardiovascular disease risk factors. HIAO is a rare form of medically induced obesity resulting from damage to the hypothalamus following resection of central nervous system tumors such as craniopharyngioma. The hypothalamus is a homeostatic control center in the brain that provides oversight of multiple hormonal systems, metabolic rate, hunger, and satiety. Patients affected by HIAO fail to regulate metabolism and food intake normally, resulting in rapid and intractable weight gain, treatment resistant severe obesity, and associated co-morbidities. Beloranib, a first-in-class MetAP2 inhibitor, that has demonstrated the potential to address weight loss and hunger reduction in patients with obesity, is being studied for the treatment of multiple indications. ZAF-221 was a randomized, double-blind, placebo controlled study of twice-weekly subcutaneous injections of 1.8 mg beloranib or placebo in patients with HIAO to evaluate weight reduction and safety over four weeks, followed by an optional four week open-label extension. Beloranib treatment resulted in mean weight loss of 3.4 kg and 6.2 kg in patients with HIAO after four and eight weeks of treatment with beloranib, respectively, in contrast to 0.3 kg mean weight loss in patients treated with placebo for four weeks (p= 0.01). Improvements in cardiovascular disease risk factors of lipids and inflammation (measured by C-reactive protein) were also observed. Beloranib 1.8 mg was well tolerated in this population, with no serious or severe adverse events reported. Safety measures such as laboratory, electrocardiogram, and vital sign measurements revealed no signals of concern, and all subjects randomized to beloranib completed the trial. This trial enrolled 14 obese patients (nine women and five men) who were confirmed by magnetic resonance imaging (MRI) to have had hypothalamic injury.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|